Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | SPAST | Q9UBP0 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 6/20 | 0.43 |
| ▸ | HTR1D | P28221 | 6/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.43 |
| ▸ | HTR1B | P28222 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428165 | 0.78 | NCF1 (0.69) | NCF1ADRB2ADRB1CYP2C9HTR1A | |
| SCHEMBL6517863 | 0.74 | HTR1A (0.47) | NCF1CYP2C9HTR1AHTR1DSLC6A4 | |
| SCHEMBL4176462 | 0.74 | NCF1 (0.72) | NCF1ADRB2ADRB1CYP2C9HTR1A | |
| SCHEMBL22302991 | 0.74 | ADRB1 (0.57) | LATS1ADRB1CYP2C9HTR1AHTR2C | |
| SCHEMBL2877579 | 0.73 | ADRB1 (0.54) | LATS1ADRB1HTR1AHTR2CHTR2B | |
| SCHEMBL2877578 | 0.73 | ADRB1 (0.54) | LATS1ADRB1HTR1AHTR2CHTR2B | |
| SCHEMBL21268736 | 0.73 | ADRB1 (0.54) | LATS1ADRB1HTR1AHTR2CHTR2B | |
| SCHEMBL2881010 | 0.73 | CYP2C9 (0.50) | NCF1ADRB2ADRB1CYP2C9HTR1A | |
| SCHEMBL4186326 | 0.73 | CHRNB2 (0.53) | HTR1AHTR1DSLC6A4HTR1B | |
| SCHEMBL429083 | 0.73 | CYP2C9 (0.50) | NCF1ADRB2ADRB1CYP2C9HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | LATS1 4350/4885NCF1 3910/4885ADRB2 456/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | LATS1 4419/4885NCF1 3681/4885ADRB2 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.